ReviewExpert opinion on therapeutic targets2015
Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.
Review in Expert opinion on therapeutic targets, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Functionalized nanomedicines for co-targeting of multiple pathways to efficiently treat thyroid cancer: prospects and challenges.Frontiers in pharmacology · 2026Review
- Radiosynthesis and Biological Evaluation of a Small-Molecule Probe for Thyroid-Stimulating Hormone Receptor.ACS medicinal chemistry letters · 2025Article
- TSHR in thyroid cancer: bridging biological insights to targeted strategies.European thyroid journal · 2025Review
- G-protein coupled receptors synergy in bone health: new avenues for osteoporosis detection andFrontiers in endocrinology · 2025Review
- Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer.Molecular imaging and biology · 2024Article
- Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.Surgery · 2024Article
- Receptor modulators associated with the hypothalamus -pituitary-thyroid axis.Frontiers in pharmacology · 2023Review
- Article
- Modeling TSH Receptor Dimerization at the Transmembrane Domain.Endocrinology · 2022Article
- Cryo-EM: A new dawn in thyroid biology.Molecular and cellular endocrinology · 2021Review
- Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation.BMC endocrine disorders · 2021Article
- Modulating TSH Receptor Signaling for Therapeutic Benefit.European thyroid journal · 2020Article
- Graves' disease.Nature reviews. Disease primers · 2020Review
- Practical applications of studies on the TSH receptor and TSH receptor autoantibodies.Endocrine · 2020Article
- Editorial: TSH Receptor and Autoimmunity.Frontiers in endocrinology · 2019Article
- Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future.International journal of endocrinology · 2018Review
- The cell biology of the thyroid-disrupting mechanism of dichlorodiphenyltrichloroethane (DDT).Journal of endocrinological investigation · 2018Review
- Antigenic "Hot- Spots" on the TSH Receptor Hinge Region.Frontiers in endocrinology · 2018Article
- Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease.BMC medicine · 2017Review
- Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro.British journal of pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe thyroid-stimulating hormone receptor (TSHR) is the essential molecule for thyroid growth and thyroid hormone production. Since it is also a key autoantigen in Graves' disease and is involved in thyroid cancer pathophysiology, the targeting of the TSHR offers a logical model for disease control. AREAS COVERED: We review the structure and function of the TSHR and the progress in both small molecule ligands and TSHR antibodies for their therapeutic potential. EXPERT OPINION: Stabilization of a preferential conformation for the TSHR by allosteric ligands and TSHR antibodies with selective modulation of the signaling pathways is now possible. These tools may be the next generation of therapeutics for controlling the pathophysiological consequences mediated by the effects of the TSHR in the thyroid and other extrathyroidal tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.